Filing Flows › Lineage Cell Therapeutics (LCTX) › Q2 2025
Lineage Cell Therapeutics (LCTX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Lineage Cell Therapeutics (LCTX) reported revenue of $2.8M for the second quarter 2025 (Q2 2025), +96% from a year earlier and +84% from the quarter before. Operating margin was -715.4%.
Lineage Cell Therapeutics, Q2 2025: revenue $2.8M (+96% year over year), operating margin -715.4%, net loss $30.4M, operating cash flow −$5.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.8M | +84% | +96% |
| Operating profit | −$19.8M | — | — |
| Net earnings | −$30.4M | — | — |
| Operating cash flow | −$5.5M | — | — |
What changed
Revenue was $2.8M in Q2 2025, up 96% year over year and up 84% from the previous quarter. Collaboration Revenues was the largest line at 92% of revenue. Collaboration Revenues added $1.4M year over year (up 131%), 106% of the total change. Royalties License and Other Revenues declined 25%.
Operating costs exceeded revenue by $19.8M, an operating margin of -715.4%. Total costs grew 210% against revenue growth of 96%. The quarter ended with a net loss of $30.4M, wider than the previous quarter's $4.1M loss.
Operating cash flow was −$5.5M. Non-cash charges added back $171K of depreciation and amortization and $1.2M of share-based compensation. Working capital and other items added $23.4M. Capital expenditures of $14K exceeded it, leaving free cash flow of −$5.6M.
Questions
What was Lineage Cell Therapeutics' revenue in the second quarter 2025?
Lineage Cell Therapeutics (LCTX) reported revenue of $2.8M for the second quarter 2025 (Q2 2025), +96% from a year earlier and +84% from the quarter before.
Was Lineage Cell Therapeutics profitable in the second quarter 2025?
Operating loss was $19.8M (-715.4% of revenue) and net loss $30.4M.